AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05432011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Femoral Cutaneous Nerve Block
Description: At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
Study NCT05432011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Infiltration
Description: At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.
Study NCT05533502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement
Description: Ingestion of the Test Product at 07.00am - Fava-bean protein concentrate dosed at 0.33 g/kg body mass and Aquamin F dosed at 800mg in 500 ml water volume. Supplied by Marigot Limited, Strand Farm Currabinny, Co. Cork, Ireland
Study NCT05533502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Ingestion of the Control Product at 07.00am - 500ml water volume.
Study NCT04558151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preoperative inspiratory muscle training
Description: Physiotherapists will measure the maximal inspiration pressure (MIP) with the POWER®breathe device of each single patient. Patients will then be instructed to perform inspiratory muscle training at the level of 60% of their individual MIP. Patients are instructed to perform the training containing of 30 breaths twice a day for 14-18 days before surgery. The devices are able to register the performance of each single training session and training results are monitored.
Study NCT04816669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection
Study NCT06287099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRL-101
Description: Subjects will receive a single infusion of BRL-101.
Study NCT05676021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: motivational interview-based health education
Study NCT05592587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the effectiveness of eye massage device producing both vibrations and nature sounds distraction in the management of anxious pediatric patients during inferior alveolar nerve.
Description: The child will be provided inferior alveolar nerve during eye massage device producing both vibrations and nature sounds. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale
Study NCT05592587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the effectiveness of eye massage device producing vibratory stimulations distraction in the management of anxious pediatric patients during inferior alveolar nerve.
Description: The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale
Study NCT05592587 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during inferior alveolar nerve.
Description: The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale
Study NCT04785469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-load eccentric training
Description: * Aerobic exercise training on a downhill walking treadmill with the following settings: 10% negative incline and constant speed corresponding to 75% of the average speed recorded during the initial 6-Minute walk test.~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 3 sets for 10 repetitions of the leg extension (performed unilaterally in eccentric phase) with a load of 75% of 1 repetition maximum (concentric) for the first two weeks. The following two weeks, 3 sets for 10 repetitions will be performed on the leg press (performed unilaterally in the eccentric phase) with 75% load of 1 repetition maximum (concentric). In addition, patients will perform 3 upper extremity strengthening exercises (free weights or elastic bands), including 2 sets of 10 repetitions for each exercise.
Study NCT04785469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: * Aerobic exercise training using the cycle ergometer at an intensity calculated as follows: 2 minutes with load equal to 20% of maximum load, then 25 minutes with initial load at 50% of maximum load calculated as 103.217 + (30.500xGender) + (-1.613xAge) + \[0.002x6-Minute walk work (6MWW)\]. \[Sex: female = 0; male:1\] \[6MWW = 6-Minute walk distance x weight in kg\].~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 5 exercises for upper and lower limbs performed with free weights or elastic bands. For the first 2 weeks will be performed 2 sets X 20 repetitions with 1 minute break between sets and a load that allows to perform no more than 20 repetitions. For the following 2 weeks, 3 sets of 10 repetitions x 10 repetitions with 2 min break between sets and a load that allows for no more than 10 repetitions.
Study NCT04884178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trifocal Preloaded IOL Delivery System
Description: UV and blue-light filtering foldable trifocal IOL with a +2.2 diopter (D) addition power of intermediate visual acuity and a +3.3 D addition power of near visual acuity. This device is approved in Taiwan.
Study NCT06522126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercise
Description: One of the techniques employed to mitigate the prevalence of PMS complaints in women during this period is progressive relaxation exercises (PRE). It is one of the most preferred options due to its simplicity, cost-effectiveness, and reliability. Over the course of numerous years of research, progressive relaxation has been validated as an efficacious approach for regulating muscle tension. These exercises are performed to facilitate the distinction between tension and looseness in the body and to enable the individual to relax on her own in daily life. PRE involves the voluntary, systematic tension and relaxation of large muscle groups in the human body. PRE reduces anxiety levels by reducing muscle tension. It also provides the individual with a sense of profound rest, renewal, and rebirth.
Study NCT05349565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL PHYSICAL THERAPY
Description: High frequency TENS for 10 mins, 3 days/week Ankle pumps for blood circulation 10 repetitions x1 set, 3 days/week. Heel slides10 repetitions x1 set, 3 days/week. Open chain knee flexion and extension 10 repetitions x1 set, 3 days/week. SLR (straight leg raise) 10 repetitions x1 set, 3 days/week. Calf stretch 10 repetitions x1 set, 3 days/week. Quad set 10 repetitions x1 set, 3 days/week.~Total 6 sessions each consisting of 30-45 minutes
Study NCT05349565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUSCLE ENERGY TECHNIQUE
Description: Experimental group treated by applying Muscle energy technique along conventional physical therapy.~For MET patient is positioned at maximal comfort and lengthening while engaging the barrier and then patient is asked to perform isometric contraction with 6-10 sec hold and then release and lengthen the muscle 4-5 repetition x 1 set, 3days/week Total 6 sessions each consisting of 30-45 minutes
Study NCT06361108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YJ001 for Spray Use
Description: Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)
Study NCT06361108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of YJ001 for Spray Use
Description: Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water
Study NCT05765513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)
Description: The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.
Study NCT05613465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codonopsis
Description: Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
Study NCT05613465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is packaged in the same package as the drug
Study NCT06518408 — intervention group
Intervention type: DRUG
Intervention: Cabotegravir Injectable Product
Description: long-acting regimen dosed every 2-months
Study NCT06518408 — intervention group
Intervention type: DRUG
Intervention: Rilpivirine Injectable Product
Description: long-acting regimen dosed every 2-months
Study NCT06139770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family based therapy- Metacognitive therapy
Description: Family based therapy and Metacognitive therapy
Study NCT05417763 — intervention group
Intervention type: DEVICE
Intervention: Randomized physiological measurements by the two systems
Description: To measure physiological indices (FFR, cRR and RFR), either pressure microcatheter or pressure wire enters one patient's body. Whether it is the pressure microcatheter or pressure wire firstly to enter is randomized. After completion of one system's physiological assessment, the other system will follow for its physiological assessment.
Study NCT04950621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: Remimazolam will be administered during induction and maintenance for general anesthesia.
Study NCT04950621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol will be administered during induction and maintenance for general anesthesia.
Study NCT05418205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Families with FGP support
Description: Non-randomized controlled trial with four points of measurement ( in 18 months)
Study NCT05252091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herombopag olamine tablets
Description: The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
Study NCT06248775 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prehabilitation Intervention Supported with Technology (Fitbit, glucose sensor and app for diet habits)
Description: During the VITAAAL intervention patients use the Diameter app to monitor their physical activities (in connection with a Fitbit), nutrition (using the Diameter app) and glucose levels (in connection with Freestyle Libre 2 sensors). Before the intervention starts, a three-day period of blinded baseline measurements is performed to measure current habits, motivation and possibilities. Then, individual aims for improving vitality are formulated in consultation with the NP diabetes. Afterwards, patients continue measuring their habits unblinded with the Diameter for the following weeks and weekly evaluate their goals with the nurse practitioner to receive new instructions and/or to adapt the goals
Study NCT06520644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wii-based interactive training program
Description: include step basic, hula hoop, table tilt, jogging, jumping, single limb extension. Single limb extension
Study NCT06520644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.
Study NCT04681976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telematic dance program
Description: Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises.
Study NCT05862168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.
Study NCT05862168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
Study NCT05862168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m\^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.
Study NCT05862168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
Study NCT04354649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 5mg/kg PO daily
Study NCT04354649 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydroxychloroquine-matching placebo
Study NCT05615519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.
Description: Digital ruler of strabismus
Study NCT04845711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: patients will receive general anesthesia only.
Study NCT04845711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block group
Description: patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
Study NCT04845711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block group
Description: patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
Study NCT06453889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimode thermal therapy
Description: The multimode thermal therapy procedure consists of a sequential rapid freezing, natural thawing, and radio-frequency (RF) heating of the target tumor tissue.
Study NCT05304533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days
Study NCT05304533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days
Study NCT05304533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Specified dose on specified days
Study NCT05130515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200mg po QD, day1\~21
Study NCT05130515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 10mg po QD, day1\~14, 3 weeks/cycle
Study NCT04638361 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: To explore the quality of life, two questionnaires will be submitted to the parents and the child. The first one is the pediatric version of the VHI (Voice Handicap Index), which explore, using 23 items, the functional, physical and emotional aspects of the dysphonia. The second one is the PEDI-EAT-10 (Pediatric Voice Handicap Index - Eating Assessment Tool), which explore, through 10 items (ranging from 0 to 4), the risk of aspiration and assess the impact of possible dysphagia on quality of life.
Study NCT05266170 — intervention group
Intervention type: DEVICE
Intervention: aerobic and anaerobic exercises
Description: \[aerobic\]~1. Aerobic treadmill walking program without EX1~2. Aerobic treadmill walking program with EX1~3. High-intensity interval exercise (HIIT) program with EX1~\[anaerobic\]~1. Fitness exercise program with EX1
Study NCT05083117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW001
Description: It is anticipated that inhalation of 1 mg XW001 solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
Study NCT05083117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is anticipated that inhalation of 1 mg Placebo solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
Study NCT05882708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: After randomization, the starting dose of ivabradine, 5mg, is given via the gastrointestinal tract every 12 hours. Heart rate control ranged from 70 to 94 bpm. Ivabradine was maintained until 96 hours after initiation of therapy. Beyond this period, the decision to continue ivabradine is left to the discretion of the treating intensivist. During the drug intervention period, heart rate is assessed before each dose. Ivabradine is tapered or discontinued if the heart rate is lower than the target rate; If the heart rate remains ≥95 bpm after 48 hours, the dose is increased to 7.5mg. If a heart rate of 95 or more bpm recurs after discontinuation during the intervention period, treatment with ivabradine can be resumed. Furthermore, Ivabradine is also discontinued at any time in the presence of severe liver impairment, malignant arrhythmia, cardiac conduction block, allergy, the need to take drugs with potentially harmful effects of ivabradine.
Study NCT05398913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant
Study NCT05398913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant
Study NCT05868122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Naproxen Sodium Fixed Combination
Description: Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
Study NCT05868122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT05577117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: drugs are injected with induction of general anesthesia
Study NCT06370429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises, randomized pretest-posttest
Description: experimental and control ,a randomized pretest-posttest study to examine
Study NCT06425692 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Education on basic palliative care via e-learning + webinar to deepen knowledge.
Study NCT04532606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.